Form 4: Establishment Labs Director Acquires Shares in Lieu of Cash Retainer

Director Dennis E. Condon acquired 298 common shares of Establishment Labs Holdings Inc. (ESTA) on December 31, 2024, in lieu of a quarterly cash retainer payment.

Summary

• On December 31, 2024, Dennis E. Condon, a director of Establishment Labs Holdings Inc. (ESTA), acquired 298 common shares.
• The shares were acquired in lieu of a quarterly cash retainer payment, as per the Issuer's Outside Director Compensation Policy.
• The price per share was $46.07.
• Following the transaction, Condon directly owns 9,385 common shares.
• The shares were issued under the Issuer's 2018 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine part of director compensation. The director taking shares instead of cash is a mildly positive signal.

Positives

• The director's decision to take shares instead of cash may signal confidence in the company's future performance.

Industry Context

Directors receiving shares in lieu of cash compensation is a fairly common practice, particularly in growth-oriented companies, as it aligns their interests with those of shareholders.

Comparison to Industry Standards

• Comparing Establishment Labs' director compensation structure to companies like Align Technology (ALGN) or InMode (INMD) could provide insights into whether this practice is standard within the medical aesthetics industry.
• Reviewing the director compensation policies of similar-sized companies in the healthcare sector can offer a benchmark for evaluating the appropriateness of this arrangement.

Stakeholder Impact

• The transaction has a minimal impact on shareholders, as it's a small number of shares.
• Employees are unlikely to be directly affected by this transaction.

Key Dates